JP2016505625A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505625A5
JP2016505625A5 JP2015552094A JP2015552094A JP2016505625A5 JP 2016505625 A5 JP2016505625 A5 JP 2016505625A5 JP 2015552094 A JP2015552094 A JP 2015552094A JP 2015552094 A JP2015552094 A JP 2015552094A JP 2016505625 A5 JP2016505625 A5 JP 2016505625A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
solid solution
solution pharmaceutical
composition according
glyceryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552094A
Other languages
English (en)
Japanese (ja)
Other versions
JP6505607B2 (ja
JP2016505625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/050636 external-priority patent/WO2014108572A1/en
Publication of JP2016505625A publication Critical patent/JP2016505625A/ja
Publication of JP2016505625A5 publication Critical patent/JP2016505625A5/ja
Application granted granted Critical
Publication of JP6505607B2 publication Critical patent/JP6505607B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552094A 2013-01-14 2014-01-14 固溶体組成物および心血管疾患における使用 Active JP6505607B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361752356P 2013-01-14 2013-01-14
US61/752,356 2013-01-14
US201361752309P 2013-02-04 2013-02-04
US61/752,309 2013-02-04
PCT/EP2014/050636 WO2014108572A1 (en) 2013-01-14 2014-01-14 Solid solution compositions and use in cardiovascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019061720A Division JP2019116498A (ja) 2013-01-14 2019-03-27 固溶体組成物および心血管疾患における使用

Publications (3)

Publication Number Publication Date
JP2016505625A JP2016505625A (ja) 2016-02-25
JP2016505625A5 true JP2016505625A5 (enExample) 2017-02-16
JP6505607B2 JP6505607B2 (ja) 2019-04-24

Family

ID=50030251

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015552095A Active JP6389190B2 (ja) 2013-01-14 2014-01-14 固溶体組成物および慢性炎症における使用
JP2015552096A Active JP6378694B2 (ja) 2013-01-14 2014-01-14 固溶体組成物および激痛における使用
JP2015552094A Active JP6505607B2 (ja) 2013-01-14 2014-01-14 固溶体組成物および心血管疾患における使用
JP2019061720A Pending JP2019116498A (ja) 2013-01-14 2019-03-27 固溶体組成物および心血管疾患における使用
JP2021139210A Active JP7250865B2 (ja) 2013-01-14 2021-08-27 固溶体組成物および心血管疾患における使用
JP2023045431A Active JP7748411B2 (ja) 2013-01-14 2023-03-22 固溶体組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015552095A Active JP6389190B2 (ja) 2013-01-14 2014-01-14 固溶体組成物および慢性炎症における使用
JP2015552096A Active JP6378694B2 (ja) 2013-01-14 2014-01-14 固溶体組成物および激痛における使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019061720A Pending JP2019116498A (ja) 2013-01-14 2019-03-27 固溶体組成物および心血管疾患における使用
JP2021139210A Active JP7250865B2 (ja) 2013-01-14 2021-08-27 固溶体組成物および心血管疾患における使用
JP2023045431A Active JP7748411B2 (ja) 2013-01-14 2023-03-22 固溶体組成物

Country Status (16)

Country Link
EP (6) EP2943222B1 (enExample)
JP (6) JP6389190B2 (enExample)
KR (6) KR102235264B1 (enExample)
CN (4) CN105007947B (enExample)
AU (4) AU2014204734B2 (enExample)
BR (3) BR112015015898B1 (enExample)
CA (3) CA2897878A1 (enExample)
ES (5) ES2829904T3 (enExample)
IL (5) IL282123B (enExample)
MX (3) MX379193B (enExample)
NZ (1) NZ709486A (enExample)
PL (1) PL3795141T3 (enExample)
RU (3) RU2674982C2 (enExample)
SG (4) SG11201505247TA (enExample)
WO (3) WO2014108574A1 (enExample)
ZA (3) ZA201505003B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
KR102235264B1 (ko) * 2013-01-14 2021-04-02 인퍼스트 헬스케어 리미티드 고용체 조성물들 및 심각한 통증에서의 이들의 용도
MX387217B (es) * 2015-08-07 2025-03-18 Infirst Healthcare Ltd Composiciones de solución sólida para aines.
US10307388B2 (en) * 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation
KR102701244B1 (ko) 2017-10-23 2024-09-02 에피트래커, 인코포레이티드 지방산 유사체 및 대사 증후군 관련 병태 치료에서의 그의 용도
AU2019271067B2 (en) * 2018-05-16 2023-08-03 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to aging
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
CN108653273A (zh) * 2018-07-13 2018-10-16 昆明医科大学第附属医院 青蒿素类化合物作为制备治疗贝赫切特病药物的应用
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
CN110251549B (zh) * 2019-06-24 2021-12-03 浙江省肿瘤医院 淫羊藿总黄酮提取物在制备防治桥本甲状腺炎的药物中的应用
WO2020259670A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 一种缓释脂质组合物及其制备方法
CA3109520C (en) * 2019-07-21 2021-09-07 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Crf受容体アンタゴニストおよび使用方法
EP4100029A4 (en) * 2020-02-03 2024-03-06 Curemast, Inc. COMPOSITIONS AND METHODS OF USING THEM FOR THE TREATMENT OF MASTITIS
RU2752764C1 (ru) * 2020-12-14 2021-08-03 Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") Фармацевтическая композиция, обладающая противовоспалительным действием
CA3212583A1 (en) 2021-03-27 2022-10-06 Daniel Gooding Compositions having improved bioavailability of therapeutics
EP4426130A1 (en) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
CN114601843A (zh) * 2022-03-22 2022-06-10 重庆医科大学附属第一医院 淫羊藿苷在制备治疗自身免疫性葡萄膜炎药物中的用途
GB202208911D0 (en) * 2022-06-17 2022-08-10 Ravan Bio Limtied Treatments
AU2023321655A1 (en) 2022-08-12 2025-02-13 Jazz Pharmaceuticals Research Uk Limited Oral solid dosage forms comprising cannabinoids

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US8663692B1 (en) * 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
BR0010354A (pt) * 1999-05-07 2002-03-05 Pharmasol Gmbh Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção
CA2377301C (en) * 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
AU7984200A (en) * 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
JP2002284705A (ja) * 2001-01-19 2002-10-03 Shiseido Co Ltd 刺激緩和剤
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
JP2007500691A (ja) * 2003-07-31 2007-01-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗炎症剤の分散性製剤
CA2540984C (en) * 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
ZA200604250B (en) * 2003-11-13 2007-11-28 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
KR20060125824A (ko) * 2003-12-01 2006-12-06 라이프사이클 파마 에이/에스 레르카니디핀을 포함한 약학적 조성물
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
BRPI0518484A2 (pt) * 2004-11-24 2008-11-18 Merck & Co Inc composiÇço, cÁpsula, e, processo para preparar a mesma
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
EA012882B1 (ru) * 2005-04-28 2009-12-30 ДСМ АйПи ЭССЕТС Б.В. Фармацевтические лекарственные формы, содержащие липидную фазу
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
RU2353349C2 (ru) * 2007-04-18 2009-04-27 Общество с ограниченной ответственностью "Фармацевтические технологии" Средство для лечения болезней суставов
CN101129335B (zh) * 2007-07-17 2010-09-22 浙江大学 一种纳米结构脂质载体给药系统的用途
US8461183B2 (en) 2008-05-26 2013-06-11 Genfit PPAR agonist compounds, preparation and uses
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
MX346224B (es) * 2011-02-04 2017-03-10 Biocopea Ltd Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
EP2688560A2 (en) * 2011-03-24 2014-01-29 Leo Pharma A/S A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
CN102793628B (zh) * 2012-08-23 2014-07-02 东华大学 用于化妆品的液-固混合脂质纳米缓释系统及其制备方法
KR102235264B1 (ko) * 2013-01-14 2021-04-02 인퍼스트 헬스케어 리미티드 고용체 조성물들 및 심각한 통증에서의 이들의 용도

Similar Documents

Publication Publication Date Title
JP2016505625A5 (enExample)
JP2016504403A5 (enExample)
JP2016508155A5 (enExample)
JP2014509655A5 (enExample)
AR109789A2 (es) Compuestos lipídicos
AR084639A1 (es) Formas polimorficas de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico y usos del mismo
JP2016504401A5 (enExample)
RU2015134142A (ru) Композиции твердых растворов и их применение при сильной боли
RU2017121460A (ru) Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
EA201100863A1 (ru) Фармацевтическая композиция, включающая диклофенак и сложный эфир гидроксижирной кислоты и полиоксиалкилена
JP2016506941A5 (enExample)
DK3000808T3 (da) 5-((halophenyl)-3-hydroxy-pyridin-2-yl)-carboxylsyre-derivater som intermediater til fremstillingen af carbonylamino-alkansyrer, estere og amider deraf
JP2014111672A5 (enExample)
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
WO2016012965A3 (en) Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
HK1251466A1 (zh) 包含pi3k抑制剂和hdac抑制剂的组合物
JP2017513836A5 (enExample)
IL236376B (en) Eicosapentaenoic acid ethyl ester for use as a medicament for reducing a risk of cardiovascular death
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
JP2017505285A5 (enExample)
JP2014122247A5 (ja) β−クリプトキサンチンを有効成分とするペルオキシソーム増殖剤応答性受容体(PPAR)の活性化剤
MX2015011074A (es) Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
JP2018526351A5 (enExample)
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)